HemoSonics

What HemoSonics does

HemoSonics is a privately held medical device company that develops and commercializes the Quantra Hemostasis System, a point-of-care viscoelastic testing (VET) platform for whole-blood coagulation analysis in acute-care hospital settings. The company is incorporated as HemoSonics, LLC, headquartered in Durham, North Carolina, with a European sales operation based in Asnières-sur-Seine, France. Its clinical footprint spans obstetric, cardiac surgery, trauma, liver transplantation, and major orthopedic surgery departments across US and European hospitals, with the September 2025 FDA 510(k) clearance for peripartum obstetric procedures establishing the Quantra System as the first and only FDA-cleared VET platform for that indication.

The core product architecture rests on a proprietary ultrasound-based technology called SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry, protected by at least 11 granted US patents. The system consists of a capital equipment analyzer (HS-002) paired with two disposable cartridge types — the QPlus Cartridge for cardiovascular and major orthopedic surgery, and the QStat Cartridge for trauma, liver transplantation, and peripartum obstetrics. Cartridge parameters include Clot Time, Clot Stiffness, Fibrinogen Contribution to Clot Stiffness, Platelet Contribution to Clot Stiffness, and Clot Stability to Lysis, with results available in approximately 5 minutes initially and 12.5 minutes complete. The platform integrates with at least seven major hospital middleware systems (Abbott RALS/Aegis, Siemens POCcelerator/UniPOC, Roche cobas, Radiometer AQURE, Data Innovations, Telcor) and participates in Stago's Qualiris external quality assessment program.

HemoSonics operates a razor-and-blade revenue model combining one-time capital equipment sales with recurring cartridge and quality control consumable revenue, supplemented by the Quantra Desktop Remote Viewer (QDRV) software (perpetual license, no annual fee) and comprehensive professional services. Go-to-market is direct enterprise field sales to hospitals in the US and Europe, supported by clinical evidence marketing (56+ publications, 67+ abstracts since 2020) and society partnerships including the Society for Maternal-Fetal Medicine. Pricing is not publicly disclosed; the company has raised approximately $17.8M cumulatively across disclosed funding events (largest a 2017 $15M round) and received a 2024 NIH RADx Tech grant of $525,000 for the obstetric application.

Name

HemoSonics

Legal name

HemoSonics, LLC

Website

https://hemosonics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

HemoSonics is a medical device company that develops the Quantra Hemostasis System, a point-of-care viscoelastic testing platform using proprietary SEER Sonorheometry ultrasound technology to characterize whole-blood coagulation for acute-care hospital departments in the US and Europe.

Ownership category

akta.pro rank

Product category

Hemostasis Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hematology & Coagulation Diagnostics (HLAHAAAB)

akta.pro secondary industries

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC)

Keywords

• Viscoelastic hemostasis testing
• Point-of-care coagulation diagnostics
• Whole blood hemostasis analyzers
• Peripartum hemorrhage diagnostics
• Sonorheometry blood analysis

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Quantra Hemostasis Analyzer Hardware Sales: HemoSonics sells the Quantra Hemostasis Analyzer (part number HS-002) as capital equipment to hospitals and healthcare facilities. The analyzer is the hardware platform on which QPlus and QStat cartridges are run.
2. QPlus and QStat Cartridge Sales: The company sells disposable cartridges (QPlus and QStat) in kits of 10. These are recurring consumable revenue streams as cartridges are used per test. Both cartridge types can be stored at room temperature. Pricing is provided through sales representatives.
3. Quality Control Kit Sales: External biological Quality Control materials (Level 1 and Level 2) are sold separately for both QPlus and QStat cartridges. These support laboratory-defined requirements and IQCP compliance, representing a recurring consumable revenue stream.
4. Quantra Desktop Remote Viewer (QDRV) Software: QDRV software (part number KT-0039) is sold as a PC application. Each purchase includes one year of free updates. There is no annual license fee. Software enables remote viewing of real-time and historical results from networked Quantra analyzers.
5. Professional Services and Implementation Support: HemoSonics provides comprehensive installation, validation, training, algorithm development, clinical affairs support, professional education, and ongoing business review services to healthcare facilities implementing the Quantra System. These support services are offered as part of the partnership approach to drive adoption and long-term value.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

HemoSonics develops and sells the Quantra Hemostasis System, a cartridge-based point-of-care viscoelastic testing (VET) platform that uses proprietary SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry ultrasound technology to measure clot time, clot stiffness, fibrinogen contribution, and platelet contribution in whole blood. The system consists of the Quantra Hemostasis Analyzer hardware paired with QPlus Cartridges (cardiac and major orthopedic surgery) and QStat Cartridges (trauma, liver transplantation, and peripartum obstetric procedures), and is sold to acute-care hospitals in the USA and Europe.

Product overview

HemoSonics offers the Quantra Hemostasis System, a cartridge-based whole blood viscoelastic testing (VET) platform for point-of-care and laboratory coagulation analysis. The system consists of the Quantra Hemostasis Analyzer as the core hardware platform, paired with two distinct cartridge types: the QPlus Cartridge for cardiovascular and major orthopedic surgeries, and the QStat Cartridge for trauma, liver transplantation, and peripartum obstetric procedures. Supporting products include Quantra Quality Control Kits for quality assurance, the Quantra Desktop Remote Viewer (QDRV) software for facility-wide result monitoring, and the Qualiris EQA Proficiency Program for external quality assessment. Accessories include the Quantra Printer and Cleaning Cartridge.

Differentiator

Problem solved

Functional benefit

Brands

• Quantra Hemostasis System: Point-of-care viscoelastic testing (VET) platform for whole blood hemostasis analysis, including the Quantra Analyzer and QPlus/QStat cartridges.
• QPlus Cartridge
• QStat Cartridge
• SEER Sonorheometry
• Qualiris EQA Proficiency Testing Program

Products and services

• Quantra Hemostasis Analyzer The main whole blood hemostasis analyzer device (part number HS-002) that uses proprietary SEER Sonorheometry ultrasound technology to measure viscoelastic properties of blood for point-of-care and laboratory coagulation testing. Sold as capital equipment to hospitals and healthcare facilities.
• QPlus Cartridge A disposable cartridge (part number KT-0004, kits of 10) for the Quantra System indicated for cardiovascular and major orthopedic surgeries, providing Clot Time, Clot Time with Heparinase, Clot Stiffness, Fibrinogen Contribution to Clot Stiffness (FCS), and Platelet Contribution to Clot Stiffness (PCS) measurements.
• QStat Cartridge A disposable cartridge (part number KT-0020, kits of 10) for the Quantra System indicated for trauma, liver transplantation, and peripartum obstetric procedures, providing Clot Time, Clot Stiffness, and Clot Stability to Lysis measurements including TXA comparison.
• Quantra Quality Control Kits External biological quality control materials (Level 1 and Level 2) supplied in kits of 4 for the Quantra System. Supports the development of Individual Quality Control Plans (IQCP) and verifies performance of cartridge parameters for QPlus and QStat.
• Quantra Desktop Remote Viewer (QDRV) PC application software (part number KT-0039) that allows remote viewing of real-time screens from any networked Quantra analyzer, enabling viewing of dials, trends, curves, and historical results across facility-wide Windows workstations. Sold as a one-time perpetual license with one year of free updates and no annual license fee.
• Qualiris EQA Proficiency Program External Quality Assessment (EQA) proficiency testing program for the Quantra System with QPlus and QStat Cartridges, offered in partnership with Stago. Provides peer-to-peer comparison and comprehensive statistical analysis across global laboratories with Spring and Fall test materials in one kit.
• Quantra Printer Accessory for the Quantra Hemostasis Analyzer that enables printing of numeric results.
• Quantra Cleaning Cartridge Accessory for use with the Quantra Hemostasis Analyzer intended for periodic cleaning of the system.

Quantifiable outcome

• Reduced unnecessary blood product usage — VET has been demonstrated in clinical studies to reduce transfusion requirements in cardiac surgery and trauma patients.
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Stago (sthEMe Qualiris)coreStrategic or Co-development PartnerStago's sthemE Qualiris is a trusted External Quality Assessment (EQA) Proficiency Testing program supporting hemostasis and thrombosis testing worldwide. The program provides Spring and Fall test materials in one kit for peer-to-peer comparison across a global participant group for both QPlus and QStat cartridges. Qualiris enables laboratories to confidently assess proficiency test results through detailed comparisons among a diverse global peer group.
• Abbott (RALS Data Management, Aegis POC)coreTechnology or IntegrationAbbott's RALS Data Management System and Aegis POC middleware integrate with the Quantra System to enable scalable POC device deployment, centralized QC and user management, EMR/EHR/LIS data transfer, and compliance with POC connectivity standards (CLSI POCT01-A2, CLSI LIS02-A2).
• Siemens Healthineers (POCcelerator, UniPOC)coreTechnology or IntegrationSiemens Healthineers POCcelerator and UniPOC middleware solutions provide integrated connectivity for the Quantra System, enabling hospitals to centralize POC device data, manage operator certifications, monitor QC results, and send patient test results to EMR/EHR/LIS systems.
• Roche (COBAS IT 1000 / Infinity)supportingTechnology or IntegrationRoche's COBAS IT 1000 and Infinity POC middleware platforms integrate with the Quantra System to enable connectivity to EMR/EHR/LIS systems, supporting scalable POC deployment across hospital institutions.
• Radiometer (AQURE)supportingTechnology or IntegrationRadiometer's AQURE middleware platform provides connectivity for the Quantra System, enabling centralized POC device data management, QC monitoring, and integration with hospital information systems.
• Data Innovations (Instrument Manager)supportingTechnology or IntegrationData Innovations Instrument Manager provides middleware connectivity for the Quantra System, enabling integration with hospital laboratory and POC IT infrastructure for data management and reporting.
• Telcor (QML)supportingTechnology or IntegrationTelcor QML middleware integrates with the Quantra System to support POC connectivity, enabling transfers of results to EMR/EHR/LIS, centralized QC management, and operator certification tracking.
• Society for Maternal-Fetal Medicine (SMFM)supportingGTM or Marketing PartnerHemoSonics joined SMFM as an Ambassador during High-Risk Pregnancy Awareness Week (June 1-8, 2026) to support clinicians and organizations dedicated to improving outcomes in high-risk pregnancy care through greater awareness and collaboration.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers: Siemens Healthineers is a broad incumbent in hospital hemostasis and POC diagnostics with POCcelerator and UniPOC middleware that integrate with Quantra. Siemens offers its own coagulation analyzers and competes for the same hospital blood-gas / coagulation testing budgets.
• Abbott: Abbott is a broad incumbent in hospital diagnostics whose RALS and Aegis POC middleware platforms integrate with the Quantra System. Abbott also offers its own coagulation/POCT portfolio (iSTAT and central lab analyzers), making it an adjacent competitor as well as a connectivity partner.
• Radiometer: Radiometer (a Danaher company) provides the AQURE middleware platform used to integrate Quantra analyzers and is itself a global incumbent in blood gas and acute-care diagnostics, including adjacent POCT menus that compete for hospital POC budgets.
• Roche Diagnostics: Roche provides cobas IT 1000 / Infinity middleware that integrates with Quantra and is a broad incumbent in central laboratory and POC diagnostics, including coagulation testing — comparable as both an integration partner and a partial competitive overlap.

Emerging players

• Stago: Stago is a global hemostasis diagnostics specialist and HemoSonics' strategic partner for the Qualiris EQA program; Stago also distributes related hemostasis instrumentation and reagents (e.g., qLabs FIB) and is therefore both a partner and a partial competitor in coagulation diagnostics.

Others

• Data Innovations: Data Innovations provides Instrument Manager middleware that integrates with the Quantra System for laboratory and POC data management — an ecosystem enabler rather than a direct competitor in hemostasis testing.
• Telcor: Telcor provides QML middleware used to integrate Quantra analyzers with EMR/EHR/LIS systems — an enabling infrastructure vendor comparable to HemoSonics' integration strategy rather than a direct diagnostic competitor.

Direct peers

• Haemonetics: Haemonetics manufactures the TEG (Thromboelastography) hemostasis analyzer portfolio — the most direct global VET competitor to the Quantra System across cardiac surgery, trauma, and transplant. HemoSonics competes head-to-head against TEG for the same hospital point-of-care hemostasis budget.
• Werfen (ROTEM / Instrumentation Laboratory): Werfen's ROTEM viscoelastic testing system (via Instrumentation Laboratory) is the second global VET incumbent alongside TEG. ROTEM directly competes with Quantra in the same perioperative and trauma indications and shares similar cartridge-style consumable economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Hemosonics
• LinkedInlinkedin.com/company/hemosonics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HemoSonics